CNCR Investor Materials


The Loncar Cancer Immunotherapy ETF

Want to learn more about the Loncar Cancer Immunotherapy ETF?
Download ETF prospectuses, summaries, SAIs, investor fact sheets and more.

Download Investor Materials

Why Cancer Immunotherapy?

Immunotherapy is a transformational field within the biotechnology space that may have a foundational impact on cancer care. By developing immunotherapies that are more effective and may deliver a better quality of life than currently available medicines, innovative immunotherapy companies may be making a difference for courageous patients who battle cancer. Our ETF seeks to support this important work and its positive impact on society.


We’re excited to be a part of the special cancer supplement in the June 29 issue of USA Today’s New York, Los Angeles, Boston, Washington DC, Baltimore, and Seattle editions. The advertisement showcases our CNCR ETF and we’re proud to be a part of important field of cancer immuotherapy.